



NDA 210854/S-021
NDA 214410/S-007

**SUPPLEMENT APPROVAL
FULFILLMENT OF POSTMARKETING REQUIREMENTS**

Genentech, Inc.
Attention: Shweta Kotwal, MBBS, MA
Regulatory Program Management
1 DNA Way
South San Francisco, CA 94080

Dear Shweta Kotwal:

Please refer to your supplemental new drug applications (sNDAs) dated and received July 2, 2024, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Xofluza (baloxavir marboxil) tablets (NDA 210854) and Xofluza (baloxavir marboxil) granules for oral suspension (NDA 214410).

These Prior Approval supplemental new drug applications provide for the following:

- To update the Prescribing Information with additional information regarding pediatric patients from birth to < 1 year of age

APPROVAL & LABELING

We have completed our review of these applications, as amended. These are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Patient Package Insert), with the addition of any labeling

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in these supplemental applications, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We note that you have fulfilled the pediatric study requirement for birth to less than 1 year of age for these applications.

FULFILLMENT OF POSTMARKETING REQUIREMENTS

We have received your submissions dated December 20, 2023 and February 27, 2024, containing the final reports for the following postmarketing requirements listed in the October 24, 2018 (NDA 210854 for PMR 3503-1), November 23, 2020 (for PMR 3961-1) approval letters, and December 16, 2020 General Advice New PREA PMR Set Numbers (NDA 214410/Original 1 for PMR 3984-1) letter.

Under NDA 210854

3503-1 Conduct a single-arm, open-label clinical trial to evaluate

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

pharmacokinetics, safety, and antiviral activity of baloxavir marboxil in pediatric subjects from birth to less than 12 months of age with acute uncomplicated influenza. Include characterization of baloxavir-resistant substitutions in viral isolates from subjects with prolonged viral shedding.

Under NDA 214410/Original 1

- 3984-1 Conduct a single-arm, open-label clinical trial to evaluate pharmacokinetics, safety, and antiviral activity of baloxavir marboxil in pediatric subjects from birth to less than 12 months of age with acute uncomplicated influenza. Include characterization of baloxavir-resistant substitutions in viral isolates from subjects with prolonged viral shedding.

Under NDA 214410/Original 1 and NDA 210854/S-004 – Post-exposure prophylaxis

- 3961-1 Submit the clinical study reports including the pharmacokinetic/ pharmacodynamic modeling data and the supporting PK, safety and efficacy data from all the relevant studies in adult and pediatric patients to extrapolate efficacy of baloxavir marboxil in pediatric subjects from birth to less than 12 months of age for the prevention of influenza as post-exposure prophylaxis in household contacts of an index case. Include characterization of baloxavir-resistant substitutions including supporting datasets.

We have reviewed your submissions and conclude that the above requirements were fulfilled.

We remind you that there is one postmarketing requirement listed in the October 24, 2018 approval letter that is still open.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.³

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication

³ For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

[21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

PATENT LISTING REQUIREMENTS

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of the supplement for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)). You also must ensure that any changes to your approved NDA that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplement pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Saebyeol Jang, Senior Regulatory Project Manager at 240-402-9953 or saebyeol.jang@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Wendy Carter, DO
Director
Division of Antivirals
Office of Infectious Diseases
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
 - Prescribing Information
 - Patient Package Insert

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

YODIT BELEW
12/19/2024 11:30:41 AM